Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(13 sites)

United States

City of Hope Comprehensive Cancer Center, Duarte, California

Los Angeles General Medical Center, Los Angeles, California

USC / Norris Comprehensive Cancer Center, Los Angeles, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

Northwestern University, Chicago, Illinois

University of Kentucky/Markey Cancer Center, Lexington, Kentucky

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland

Wake Forest University Health Sciences, Winston-Salem, North Carolina

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas

M D Anderson Cancer Center, Houston, Texas

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin

University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin